A pharmacovigilance vendor may process thousands of safety cases correctly during qualification and still become a compliance risk months later because of staff turnover, system changes, subcontracting, increasing workloads, missed timelines, or unresolved deviations, this is the reason that approving a vendor once is not the same as controlling outsourced pharmacovigilance continuously.
For Marketing Authorisation Holders (MAHs), outsourcing can transfer the execution of activities such as case processing, literature monitoring services, safety database management, aggregate reporting or local safety support. It does not transfer the MAH’s ultimate responsibility for its pharmacovigilance system.
EU GVP Module I specifically expects contractual arrangements to define delegated activities, interactions, data exchange and timelines and to include mechanisms for checking whether those arrangements continue to be followed. Risk-based audits or other methods of ongoing control are recommended.
Effective pharmacovigilance vendor management therefore has two distinct stages:
- Qualification asks whether a vendor can perform the activity.
- Ongoing oversight demonstrates whether the vendor continues to perform it compliantly once the work has started.
Why PV Vendor Qualification is Not the Same as Ongoing Oversight?
PV vendor qualification is primarily a pre-engagement decision. It gives the MAH evidence that a prospective vendor has the people, processes, systems, experience and quality controls needed for the activities it will perform.
Ongoing oversight begins after those activities become operational.
PV Vendor Qualification | Ongoing Vendor Oversight |
Determines initial suitability | Confirms continued performance |
Typically occurs before go-live | Continues throughout the relationship |
Reviews capabilities and controls | Reviews actual operational evidence |
Examines SOPs, systems and resources | Monitors KPIs, deviations and trends |
Supports vendor-selection decisions | Supports intervention and escalation decisions |
Provides a baseline risk assessment | Reassesses risk as conditions change |
The distinction matters because qualification only tells an MAH what the vendor could reasonably be expected to do at a point in time. Oversight shows what the vendor is doing over time.
A vendor that passed qualification may later experience:
- Increasing case-processing backlogs
- Reporting delays
- Staff attrition
- Repeated quality errors
- System upgrades
- Failed reconciliations
- New subcontractors
- Overdue CAPAs
- Significant inspection or audit findings
Continuous control therefore cannot be demonstrated using the original qualification report alone.
What Regulators Expect When MAHs Outsource PV Activities
EMA states that an MAH may subcontract pharmacovigilance activities but retains ultimate responsibility for the system and for the completeness and accuracy of the Pharmacovigilance System Master File (PSMF). Detailed written agreements should define responsibilities and the conduct of pharmacovigilance activities.
EU GVP Module III also allows inspectors to inspect firms employed by an MAH to perform pharmacovigilance obligations, not just the MAH itself. The same principle is visible in UK inspection practice. MHRA states that activities performed by service providers are assessed during MAH inspections and that contracts should support access to relevant data, documentation and vendor assistance during inspections.
The contract or Safety Data Exchange Agreement is important, but an agreement alone does not prove that the operating model works.
What Should Be Checked During PV Vendor Qualification?
There is no single regulator-prescribed qualification checklist that applies identically to every type of PV vendor. The depth of qualification should reflect the risk and scope of the delegated activity. A vendor performing safety-database hosting or global ICSR processing requires a different level of assessment from a provider translating individual documents.
A practical qualification assessment can examine the following areas:
- Regulatory and PV Capability
Assess:
- Relevant pharmacovigilance experience
- Markets and regulatory frameworks supported
- Understanding of applicable GVP and local requirements
- Experience with the proposed products or activities
- Ability to meet required regulatory timelines
- Quality Management System
Review whether the vendor has appropriate:
- SOPs and work instructions
- Deviation management
- Change control
- CAPA management
- Training controls
- Document management
- Audit arrangements
- Quality-review processes
- Personnel and Capacity
Qualification should determine whether the vendor has enough appropriately trained personnel to perform the expected workload.
This should include not only current headcount but also:
- Role qualifications
- Training status
- Backup coverage
- Workload management
- Escalation paths
- Business-continuity arrangements
- Systems and Data Controls
For technology-dependent services, evaluate:
- System fitness for intended use
- Validation or qualification evidence
- Access controls
- Audit trails
- Data integrity ALCOA Principles
- Backup and recovery
- Cybersecurity interfaces where relevant
- Change-management controls
EMA specifically notes that the MAH remains ultimately responsible for validation of PV processes supported by electronic systems. An MAH may rely on vendor qualification documentation where it has assessed that evidence as adequate, but additional qualification or validation activities may be necessary based on documented risk.
- Subcontracting
Determine whether the vendor intends to use subcontractors. The MAH needs visibility into activities that may move beyond the primary contracted provider, particularly where subcontractors can access safety information or perform regulatory-critical tasks.
- Previous Compliance History
Where available and relevant, consider:
- Previous audit findings
- Regulatory inspection information
- Major quality incidents
- Recurring deviations
- Significant CAPA history
What Should MAHs Monitor After Vendor Qualification?
Once operational work begins, oversight should focus on evidence. This is where pharmacovigilance vendor management becomes a continuous quality process.
Operational Performance
Depending on the outsourced activity, useful metrics may include:
- ICSR processing timeliness
- Regulatory submission timeliness
- Case quality or error rates
- Literature-screening compliance
- Reconciliation completion
- Follow-up performance
- Aggregate-report delivery
- Signal-management milestones
- Training compliance
Quality Events
The MAH should track:
- Deviations
- Repeated errors
- Missed regulatory timelines
- Complaints
- Quality incidents
- Audit findings
- Significant system or process failures
Change Management
Vendor risk should be reassessed when significant changes occur, such as:
- Acquisition or merger
- Major staff turnover
- New subcontractors
- Safety-database migration
- Automation changes
- Offshoring of activities
- Material increase in workload
- Changes to the contracted scope
CAPA Management
CAPA management is particularly important because completing a CAPA administratively is not the same as proving that the underlying problem has been corrected.
MHRA states that inadequate CAPA responses can result in compliance escalation and potentially earlier re-inspection. It also expects relevant service-provider findings to be assessed for broader impact where appropriate.
How Should MAHs Risk-Rank PV Vendors?
Not every vendor requires identical oversight. A vendor responsible for global case intake and regulatory reporting presents a different potential patient-safety and compliance impact from a low-volume translation provider. A risk-based approach helps concentrate governance where failures would matter most.
Example Vendor Risk Factors
An MAH may classify vendors as high, medium or lower risk and adjust governance accordingly. EMA GVP Module IV supports a documented risk-based approach to PV auditing, considering both the probability and potential impact of failures, with public-health risk taking priority.
How Can MAHs Demonstrate Continuous PV Vendor Control During Inspection?
For pharmacovigilance inspection readiness, the strongest evidence is not a single perfect vendor file. It is traceability across the entire vendor lifecycle. Inspectors should be able to see that risks were identified and acted on rather than simply documented.
Useful evidence may include:
- Approved vendor qualification records
- Current contracts and PV agreements
- Responsibility matrices
- Vendor and subcontractor inventories
- PSMF documentation
- Training records
- Meeting minutes
- KPI/KRI dashboards
- Reconciliation records
- Deviations and investigations
- CAPA records and effectiveness checks
- Audit reports
- Vendor reassessments
- Documented escalation decisions
A particularly relevant 2026 example came from an FDA Form 483 issued in March. The observation stated that a sponsor had not followed its written PV-vendor qualification and auditing procedures, citing the absence of initial qualification, annual reassessment and a contract-required audit. A Form 483 is an inspection observation rather than a final FDA compliance determination, but it illustrates why an MAH’s own procedures and agreements must be implemented.
Continuous control means being able to show not only what the procedure requires, but evidence that the procedure was followed.
How Technology and AI Are Changing PV Vendor Oversight in 2026
Technology can make oversight more continuous, but it can also introduce new vendor risk.
Modern dashboards can combine:
- Processing timeliness
- Submission compliance
- Quality-error trends
- Workload
- Reconciliation status
- Deviations
- Overdue CAPAs
- Vendor-specific risk indicators
AI and machine-learning tools are also increasingly relevant to PV activities such as adverse-event report management and signal detection. EMA’s adopted reflection paper recognizes potential AI/ML applications in post-authorisation pharmacovigilance while emphasizing risk management services, fitness for purpose, traceability and appropriate lifecycle controls.
EMA and US-FDA jointly published ten principles for good AI practice in the medicines lifecycle in January 2026, covering AI used across development and safety monitoring. EMA, FDA, Health Canada and PMDA also participate in an international AI in pharmacovigilance cluster, which exchanges regulatory experience and explores alignment around AI-supported PV processes.
For MAHs, the practical consequence is important:
Using an AI-enabled vendor does not remove the need for oversight. It creates additional areas that may need oversight.
Depending on the context and risk, these may include:
- Intended use
- Validation evidence
- Model performance
- Human review
- Data quality
- Change control
- Access to technical documentation
- Model or workflow changes
- Performance degradation
- Exception handling
- Audit/Inspection support
AI can improve surveillance of vendor performance, but automation should not become a black box between the MAH and its regulatory responsibilities.
A Practical Continuous PV Vendor Oversight Framework for MAHs
A scalable model can be organized around six controls:
- Qualify
Confirm the vendor is suitable for the exact PV activity before relying on it.
- Contract
Define responsibilities, safety-data flows, timelines, escalation, subcontracting, audit rights, system ownership and inspection support.
- Risk-Rank
Assess criticality based on patient-safety impact, regulatory activity, data access, system dependency, volume and previous performance.
- Monitor
Track relevant KPIs, KRIs, reconciliations, changes, deviations, training and operational performance.
- Correct
Investigate failures, manage CAPAs, verify effectiveness and escalate repeated or significant issues.
- Reassess
Update vendor risk when performance, scope, organisation, systems, subcontractors or regulatory requirements change.
How DDReg Supports PV Vendor Oversight and Inspection Readiness?
DDReg’s pharmacovigilance audit and compliance services include PV-system audits, gap assessments, mock inspections, training and support for maintaining compliant pharmacovigilance quality systems. DDReg also supports review of Safety Data Exchange Agreements and preparation for regulatory inspections.
For MAHs working across multiple service providers and markets, an independent risk-based assessment can help determine whether vendor governance, agreements, performance monitoring and CAPA processes provide enough evidence of continuous control.
Conclusion
Outsourcing pharmacovigilance does not reduce the MAH’s need for control. It changes how that control must be demonstrated.
PV vendor qualification establishes whether a provider is suitable at the start of the relationship. Ongoing oversight provides evidence that the vendor continues to operate within agreed regulatory, quality and performance expectations. The strongest pharmacovigilance vendor management systems therefore connect qualification with risk-based monitoring, documented governance, change management, audits, effective CAPA management and periodic reassessment.
Frequently Asked Questions
PV vendor qualification is the documented assessment used to determine whether a service provider has the capabilities, resources, quality systems, processes and technology needed to perform defined pharmacovigilance activities appropriately.
No. Qualification establishes initial suitability. Once activities are outsourced, the MAH needs proportionate ongoing mechanisms to verify that responsibilities, performance, quality and regulatory requirements continue to be met.
There is no single universal audit interval that applies to every vendor. Audit planning should be risk-based, considering the criticality of the outsourced activity, previous performance, changes, compliance history and potential impact on the pharmacovigilance system.
Monitoring may include regulatory timeliness, case quality, reconciliations, deviations, CAPAs, training, system changes, workload, audit findings, subcontracting and other metrics relevant to the outsourced activity.
CAPA management converts identified deficiencies into controlled remediation. Effective CAPA oversight includes root-cause assessment, defined corrective and preventive actions, ownership, deadlines, supporting evidence and effectiveness verification before closure.
Yes. AI and analytics can support activities such as performance monitoring, trend identification and parts of pharmacovigilance operations. The MAH must still ensure that AI-supported processes are fit for purpose, appropriately controlled and consistent with applicable regulatory and quality requirements.